ITCI Intra-Cellular Therapies Inc.

-0.42  -3%
Previous Close 14.09
Open 14.31
Price To Book 2.61
Market Cap 753,690,324
Shares 55,134,625
Volume 74,004
Short Ratio
Av. Daily Volume 372,660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
Agitation in patients with dementia
PDUFA date September 27, 2019. Advisory Committee Meeting July 31, 2019.
Phase 3 enrollment to be completed 2H 2019.
ITI-007 - Adjunctive Therapy
Bipolar depression
Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
Parkinson's disease (PD)

Latest News

  1. Before You Buy Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Consider Its Volatility
  2. Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options
  3. Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults
  4. Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference
  5. 2 Biotech Names See Directors Direct Cash to Their Shares
  6. Edited Transcript of ITCI earnings conference call or presentation 8-May-19 12:30pm GMT
  7. Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference
  8. Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting
  9. Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57%
  10. Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)
  11. Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript
  12. Intra-Cellular: 1Q Earnings Snapshot
  13. Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update
  14. Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast
  15. Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
  16. Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard
  17. Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
  18. Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%
  19. Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs
  20. Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference